Novo Nordisk to buy IP rights to Neose technology
This article was originally published in Scrip
Novo Nordisk is to acquire the intellectual property rights related to Neose Technologies's proprietary GlycoPEGylation technology for $21 million. The Danish company says the acquisition is in line with its strategy to expand in general haemophilia. Novo Nordisk is using the technology to develop recombinant blood clotting factors FVIIa, FVIII and FIX. GlycoPEGylation enables selective addition of polyethylene glycol (PEG) to sugar chains to extend and customise protein half-life.